CEDARS-SINAI MEDICAL CENTER Patent applications |
Patent application number | Title | Published |
20160135956 | MENISCUS FOR JOINT RECONSTRUCTION - The invention provides treatment methods of using meniscus to repair injured and/or arthritic joints, for example, small hand joints including but not limited to radiocarpal, metacarpophalangeal, and interphalangeal joints. The invention also provides various implants made of meniscus for injured and/or arthritic joints. | 05-19-2016 |
20160115192 | ANTIOXIDANT, ANTI-INFLAMMATORY AND ANTICANCER DERIVATIVES OF TRIPTOLIDE AND NANOSPHERES THEREOF - This invention relates to uses of conjugates of triptolide nanoprodrugs in cancer immunotherapy, specifically compound such as D-I or D-II wherein X | 04-28-2016 |
20160104279 | METHOD AND SYSTEM FOR "PUSH-BUTTON" COMPREHENSIVE CARDIAC MR EXAMINATION USING CONTINUOUS SELF-GATED 3D RADIAL IMAGING - The present invention teaches systems and methods for a simple cardiac MRI approach that (1) continuously acquires data; (2) covers the entire heart with high isotropic resolution within a few minutes; and (3) requires no physiological gating and minimal user intervention. Applications of the inventive systems and methods include, but are in no way limited to cardiac cine, myocardial perfusion, coronary MRA, delayed enhancement imaging, myocardial T1-weighted imaging for fibrosis imaging, and myocardial T2-weighted imaging for edema imaging. | 04-14-2016 |
20160103136 | METHODS AND SYSTEMS FOR DISTINGUISHING IRRITABLE BOWEL SYNDROME FROM INFLAMMATORY BOWEL DISEASE AND CELIAC DISEASE - Described herein are methods and systems for distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease. | 04-14-2016 |
20160100897 | STABILIZATION APPARATUSES AND METHODS FOR MEDICAL PROCEDURES - The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors. | 04-14-2016 |
20160090629 | VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE - Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci. | 03-31-2016 |
20160089151 | LEFT ATRIAL APPENDAGE OCCLUSION DEVICES AND METHODS - A catheter device is provided that includes an elongate body, an atraumatic member, an expandable member, and a locking device. The elongate body has a fluid flow lumen that is in fluid communication with an outlet port adjacent to a distal end of the elongate body. The atraumatic member can be at the tip of the elongate body. The expandable member is disposed proximal of the atraumatic tip and is configured to block an opening of the LAA. The locking device is disposed adjacent to the expandable member. The locking device has a first configuration in which the elongate body is coupled with the atraumatic member and second configuration in which the elongate body is uncoupled from the atraumatic member. | 03-31-2016 |
20160081578 | BIOMARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF BACK PAIN AND RELATED CONDITIONS - The present invention teaches novel methods of diagnosing and prognosing conditions associated with tissue degeneration and/or pain, including intervertebral disc degeneration, discogenic pain, osteoarthritis, rheumatoid arthritis, and articular cartilage injury. Using the inventive noninvasive imaging methods, the diagnosis and prognosis of back pain and related conditions can be quickly and accurately determined by detecting one or more biomarkers disclosed herein. | 03-24-2016 |
20160077102 | Diagnostic Biomarker to Predict Women at Risk for Preterm Delivery - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood. | 03-17-2016 |
20160069891 | DIAGNOSTIC BIOMARKER TO IDENTIFY WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers found in women that are at risk for preterm delivery. | 03-10-2016 |
20160067246 | USE OF PHOSPHODIESTERASE 5A INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY - Described herein are methods of treating muscular dystrophy, including Becker's muscular dystrophy and Duchenne muscular dystrophy. The methods comprise administering a phosodiesterase 5A (PDE5A) inhibitor, such as tadalafil, to a subject in need thereof. Administering the PDE5A inhibitor has beneficial effects such as restoring functional sympatholysis, alleviating ischemic insult to dystrophin-deficient muscle membranes, reducing use-dependent muscle injury, and thus can slow muscular dystrophy disease progression. | 03-10-2016 |
20160061842 | METHODS FOR DETECTING AND TREATING CANCER METASTASIS - The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes and contents of the large oncosomes in a subject in need thereof. Also provided herein are methods for treating cancer metastasis by specifically targeting contents of the large oncosomes. | 03-03-2016 |
20160061837 | ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI - Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described. | 03-03-2016 |
20160060335 | MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS - The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function. | 03-03-2016 |
20160048010 | STRUCTURED STANDING WAVE MICROSCOPE - Described herein is a method and apparatus that may be used in various applications, such as medical diagnosis and conducting research. In one embodiment, the subject matter extends upon the principle of standing wave microscopy by improving the resolution of subject specimen images in all three dimensions, thus achieving near isotropic resolution improvement that allows full three dimensional imaging of the subject specimen beyond the optical resolution limits of the objective lens and without the complexity and cost associated with 4 | 02-18-2016 |
20160045620 | USE OF NANOMETER-SIZED PRODRUGS OF NSAIDs TO TREAT TRAUMATIC BRAIN INJURY - The present invention describes methods of delivering derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) and nanospheres thereof as well as therapeutic agents to the injured brain tissue in subjects with traumatic brain injury. The invention also provides methods of treating traumatic brain injury and related conditions. The invention further provides methods of diagnosing traumatic brain injury. | 02-18-2016 |
20160045604 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF - The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines. | 02-18-2016 |
20160038562 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS - The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof. | 02-11-2016 |
20160017331 | TARGETING MICRORNAS MIR-409-5P, MIR-409-3P AND MIR-154* TO TREAT PROSTATE CANCER BONE METASTASIS AND DRUG RESISTANT LUNG CANCER - The present invention describes methods of treating cancer, cancer metastasis, and drug resistant cancers using miRNA inhibitors; for example, inhibitors of miR-409-5p, miR-409-3p, miR-154*. Also described are methods of using the miRNA as biomarkers; for example, to predict responsiveness to a cancer drug, to detect a disease state of cancer. | 01-21-2016 |
20160003742 | TIME-RESOLVED LASER-INDUCED FLUORESCENCE SPECTROSCOPY SYSTEMS AND USES THEREOF - The invention provides systems for characterizing a biological sample by analyzing emission of fluorescent light from the biological sample upon excitation and methods for using the same. The system includes a laser source, collection fibers, a demultiplexer and an optical delay device. All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. | 01-07-2016 |
20150381909 | SYSTEMS AND METHODS FOR RECORDING SIMULTANEOUSLY VISIBLE LIGHT IMAGE AND INFRARED LIGHT IMAGE FROM FLUOROPHORES - The invention provides systems and methods for imaging a sample. In various embodiments, the invention provides a system comprising an image sensor, a laser for emitting excitation light for an infrared or near-infrared fluorophore, a visible light source, a notch beam splitter, a notch filter, a synchronization module, an image processing unit, an image displaying unit, and light-conducting channels. In various embodiments, the present invention provides a system comprising an image sensor, a laser for emitting excitation light for an infrared or near-infrared fluorophore, a laser clean-up filter, a notch filter, a white light source, an image processing unit, an image displaying unit, and light-conducting channels. In accordance with the present invention, the image sensor can detect both visible light and infrared light. | 12-31-2015 |
20150376707 | METHODS OF DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE - The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. These methods, kits and compositions may involve detecting risk/protective variants or haplotypes, serological markers, increased or decreased gene methylation, and increased or decreased cytokine secretion. | 12-31-2015 |
20150376574 | PANCREATIC INSULIN-PRODUCING BETA-CELL LINES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression. | 12-31-2015 |
20150359845 | TRANSCRIPTION FACTOR-BASED GENERATION OF PACEMAKER CELLS AND METHODS OF USING SAME - Several embodiments disclosed herein relate generally to methods and compositions for the generation of biological pacemakers. In some embodiments, the methods comprise contacting non-pacemaker cells with one or more transcription factors (in vivo or in vitro) and inducing pacemaker functionality in the cells. | 12-17-2015 |
20150337378 | METHODS OF DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Disease and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus. | 11-26-2015 |
20150323638 | NON-INVASIVE QUANTIFICATION OF CORONARY ARTERY FRACTIONAL FLOW RESERVE USING MRI - A system for quantifying a fractional flow reserve (FFR) in a mammalian subject comprises implementing a multi-dimensional phase-contrast magnetic resonance sequence using an MRI scanner to scan a volume of interest (VOI) in the mammalian subject. The VOI comprises at least a portion of the mammalian subject's heart, one or more blood vessels, or both. A pressure gradient within a blood vessel segment of interest within the VOI is determined based on the implemented multi-dimensional phase-contrast magnetic resonance sequence. The determined pressure gradient is correlated to an FFR value. | 11-12-2015 |
20150322530 | MOLECULAR SIGNATURES OF OVARIAN CANCER - Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of ovarian cancers through generation of ovarian cancer disease signatures (OCDSs) that account for molecular heterogeneity present in gynecological cancers. An ovarian cancer fixed signature (OCFS) is described which relates to the core programming of disease development, in addition to an ovarian cancer stem cell (OCSC) signature. Development various disease signature, suggests personalized treatment strategies focused on molecular subtypes of gynecological cancers, such as triage tests for patients. | 11-12-2015 |
20150306190 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 10-29-2015 |
20150276748 | METHODS OF PROGNOSTICATING AND TREATING CANCER - The present invention relates to the prognosticating survival of subjects with cancer. More specifically, the invention relates to methods and systems to prognosticate cancer patients by assaying RANKL, NRP-1, p-NF-kB, p-c-Met, VEGF and/or RANK expression levels and comparing those levels to reference values to determine the likelihood of survival. The present invention also provides for methods of selecting appropriate therapies for patients based on their prognosis. | 10-01-2015 |
20150259748 | DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC. | 09-17-2015 |
20150233944 | DIAGNOSIS AND TREATMENT OF MOTILITY DISORDERS OF THE GUT AND BLADDER, AND OF FIBROMYALGIA - Described herein are methods and systems for the detection of anti-vinculin antibodies, for determining a presence or likely presence of a gastrointestinal motility disorder, bladder motility disorder, or fibromyalgia. Further provided are methods of selecting and/or administering a therapy based on the presence or absence of anti-vinculin antibodies. | 08-20-2015 |
20150231416 | ULTRASONIC BATH TO INCREASE TISSUE PERFUSION - The present invention describes a method of using an ultrasonic bath to enhance tissue perfusion, enhance the development of collateral blood vessels and/or enhance collateral circulation in an extremity in need thereof. Also described is an ultrasonic bath for the inventive method. | 08-20-2015 |
20150218246 | SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING - The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions. | 08-06-2015 |
20150217262 | DEVICES AND METHODS FOR PARAHYDROGEN INDUCED POLARIZATION - The present invention teaches devices and methods for hyperpolarization by parahydrogen induced polarization. The invention teaches several significant improvements over previous designs, including a heating block, an enhanced solenoid component, and pinch valves and tubing that provide a sterile environment for the sample. All of these advancements can be accomplished while keeping costs to produce the device relatively low. | 08-06-2015 |
20150216595 | OPTIMIZED METHOD OF COATING THE MICROWAVE ABLATION PROBE FOR SURGICAL APPLICATION - An ablation probe which includes a probe body with a distal and proximal end, an ablation tip at the distal end of the probe body, an anode provided proximate to the ablation tip, a coaxial cable disposed within the probe body and coupled to the ablation tip and anode so that electromagnetic energy of a predetermined frequency is communicated thereto for dielectric heating of tissue, and a Parylene C coating on at least the ablation tip and anode to electrically isolate the ablation tip and anode from tissue without interference with microwave energy transmission through the probe to the tissue. The Parylene C is a vapor deposited coating on at least the ablation tip and anode to electrically isolate the ablation tip and anode from tissue. | 08-06-2015 |
20150204882 | METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION - The invention relates to the use of enzymes, nanorods, and nanoelectronic devices to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient and to prescribe and/or administer an appropriate therapy to a subject. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention further comprises prescribing and/or administering an appropriate therapy to a subject based on the predicted probability of recurrence. | 07-23-2015 |
20150192653 | SYSTEMS AND METHODS FOR MYOCARDIAL PERFUSION MRI WITHOUT THE NEED FOR ECG GATING AND ADDITIONAL SYSTEMS AND METHODS FOR IMPROVED CARDIAC IMAGING - In some embodiments, the present application discloses systems and methods for cardiac MRI that allow for continuous un-interrupted acquisition without any ECG/cardiac gating or synchronization that achieves the required image contrast for imaging perfusion defects. The invention also teaches an accelerated image reconstruction technique that is tailored to the data acquisition scheme and minimizes or eliminates dark-rim image artifacts. The invention further enables concurrent imaging of perfusion and myocardial wall motion (cardiac function), which can eliminate the need for separate assessment of cardiac function (hence shortening exam time), and/or provide complementary diagnostic information in CAD patients. | 07-09-2015 |
20150191527 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH APO A-1 MILANO - This invention relates to the treatment of Alzheimer's disease, the reduction of the progression of Alzheimer's disease, and the alleviation of symptoms of Alzheimer's disease by administering ApoA-1 Milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an rAAV vector encoding ApoA-1 Milano or an active fragment thereof, to a mammal having Alzheimer's disease or a symptom of Alzheimer's disease. | 07-09-2015 |
20150111193 | METHODS AND SOLUTIONS FOR TISSUE PRESERVATION - Described herein are compositions and methods particularly useful in the medical arts. The compositions and methods may be used in connection with the preservation of a portion of a mammal, for example, tissues, organs, appendages, limbs, extremities, stem cells, myocytes, bone marrow, skeletal muscle as well as an array of other medical procedures, such as cardiac surgery, transplantation and/or preservation. In various embodiments, the inventive composition may be hyperoxygenated and be formulated to resemble the biochemistries of natural intracellular fluids. The inventive composition includes active ingredients to reduce ischemic, hypothermic and reperfusion injury during transplantation, thereby resulting in improved post-transplant graft function and quality, when used in connection with organ transplantation and storage procedures, for example cardiac transplantation. | 04-23-2015 |
20150110834 | FUNGAL MYCOBIOME AS PROBIOTICS, DIAGNOSTICS AND THERAPEUTICS - The present invention relates to methods of using fungal mycobiome as a means of treating and/or diagnosing diseases in a subject. In one embodiment, the present invention provides a method of diagnosing inflammatory bowel disease based on the composition of fungal strains present in the gut of a subject, and treating the subject by administering a probiotic biotherapy. In another embodiment, the present invention provides a method of diagnosing a severe form of ulcerative colitis by detecting the presence of a deficiency in dectin-1 expression in | 04-23-2015 |
20150099713 | METHOD OF TREATING CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME - Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufactiurc of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent. | 04-09-2015 |
20150086567 | ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE - The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis. | 03-26-2015 |
20150064180 | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS - The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier. | 03-05-2015 |
20150026831 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY - This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBD), such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis. | 01-22-2015 |
20140335025 | TARGETING CORROLES FOR TUMOR TOXICITY AND MRI - Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective amount of the targeted corrole nanoparticle to the subject; and imaging the condition in the subject. In addition, disclosed herein are methods of treating cancer in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; and administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject. | 11-13-2014 |
20140323551 | TARGETING MICRORNAS MIR-409-5P, MIR-379 AND MIR-154* TO TREAT PROSTATE CANCER BONE METASTASIS AND DRUG RESISTANT LUNG CANCER - The present invention describes methods of treating cancer, cancer metastasis, and drug resistant cancers using miRNA inhibitors; for example, inhibitors of miR-409-5p. Also described are methods of using the miRNA as biomarkers; for example, to predict responsiveness to a cancer drug, to detect a disease state of cancer. | 10-30-2014 |
20140322223 | TOX3 AS A BIOMARKER FOR BREAST CANCER - The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either overexpress or inducibly express TOX3. | 10-30-2014 |
20140308306 | COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY DISEASES - The invention provides compositions comprising immunogenic fragments of ApoB-100 for eliciting an immune response in a subject or vaccinating a subject, so as to treat, prevent, 5 inhibit and/or reduce symptoms of kidney diseases in the subject. The compositions include immunogenic fragments of ApoB-100, CD8+ T cells activated with immunogenic fragments of ApoB-100 or a combination thereof. | 10-16-2014 |
20140302097 | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS - Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate. | 10-09-2014 |
20140271561 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS - The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof. | 09-18-2014 |
20140248213 | COMPOSITIONS AND METHODS FOR TUMOR IMAGING AND TARGETING BY A CLASS OF ORGANIC HEPTAMETHINE CYANINE DYES THAT POSSESS DUAL NUCLEAR AND NEAR-INFRARED PROPERTIES - The present invention provides for heptamethine cyanine dyes that possess both nuclear and near-infrared imaging capabilities. These dyes can be used for imaging, targeting and detecting tumors in patients. | 09-04-2014 |
20140206636 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 07-24-2014 |
20140205654 | LIPOSOMAL VANCOMYCIN FOR THE TREATMENT OF MRSA INFECTIONS - The present invention discloses formulations of liposomal vancomycin that are highly effective in the treatment of bacterial infections, and particularly MRSA infections. The present invention further teaches methods of using the formulations disclosed herein for the treatment of bacterial infections. The inventors determined that certain formulations disclosed herein are likely to result in lower toxicity than what is normally associated with vancomycin treatment. | 07-24-2014 |
20140170069 | ASSESSMENT OF CORONARY HEART DISEASE WITH CARBON DIOXIDE - The invention provides methods for diagnosing coronary heart disease in a subject in need thereof comprising administering an admixture comprising CO | 06-19-2014 |
20140161762 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER - The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. | 06-12-2014 |
20140140931 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER - This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and anti-oxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs. | 05-22-2014 |
20140127272 | NANOMETER-SIZED PRODRUGS OF NSAIDS - The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions. | 05-08-2014 |
20140113008 | ASSESSMENT OF IRON DEPOSITION POST MYOCARDIAL INFARCTION AS A MARKER OF MYOCARDIAL HEMORRHAGE - The invention is directed to methods for diagnosing reperfusion/non-reperfusion hemorrhage and predicting cardiac arrhythmias and sudden cardiac death in subjects comprising using imaging techniques to detect regional iron oxide deposition. The invention also provides treatment methods for subject at increased risk of sudden cardiac death. | 04-24-2014 |
20140105822 | NANOSPHERES COMPRISING TOCOPHEROL, AN AMPHIPHILIC SPACER AND A THERAPEUTIC OR IMAGING AGENT - This invention relates to a nanosphere comprising tocopherol, an amphiphilic spacer and a therapeutic agent, an imaging agent, a hydrophobic antioxidant, a hydrophobic nonsteroidal anti-inflammatory drug (NSAID) derivative, a hydrophobic antioxidant and anti-inflammatory derivative of a nonsteroidal anti-inflammatory drug (NSAID), a statin lactone derivative, an antioxidant derivative of camptothecin or camptothecin analog, or a combination thereof. Methods of synthesizing the nanospheres and their use in treating, detecting or diagnosing diseases are also provided. | 04-17-2014 |
20140088406 | ASSESSMENT OF CORONARY HEART DISEASE WITH CARBON DIOXIDE - The invention provides methods for diagnosing coronary heart disease in a subject in need thereof comprising administering an admixture comprising CO2 to a subject to reach a predetermined PaCO2 in the subject to induce hyperemia, monitoring vascular reactivity in the subject and diagnosing the presence or absence of coronary heart disease in the subject, wherein decreased vascular reactivity in the subject compared to a control subject is indicative of coronary heart disease. The invention also provides methods for increasing sensitivity and specificity of BOLD MRI. | 03-27-2014 |
20140056807 | LARGE ONCOSOMES IN HUMAN TUMORS AND IN CIRCULATION IN PATIENTS WITH CANCER - The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes in a subject in need thereof. | 02-27-2014 |
20140051598 | DIAGNOSTIC BIOMARKER TO PREDICT WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood. | 02-20-2014 |
20140045775 | SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING - The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions. | 02-13-2014 |
20140045193 | METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION - The invention relates to the use of enzymes and nanorods to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. This invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject and treating the subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. | 02-13-2014 |
20140039125 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM - A drug delivery system for delivering a drug payload to a specific tissue or cell type is disclosed. The system includes a polymalic acid molecular scaffold which can be used for attaching a plurality of molecular modules. Molecular modules include targeting antibodies for promoting cellular uptake by a target cell, and pro-drugs for altering cellular metabolism, for example, a pro-drug that alters expression of protein kinase CK2. | 02-06-2014 |
20140018448 | ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE - The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis. | 01-16-2014 |
20140018447 | METHODS OF DIAGNOSING AND TREATING INTESTINAL GRANULOMAS AND LOW BONE DENSITY IN INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD). | 01-16-2014 |
20140017711 | METHODS OF DIAGNOSING ULCERATIVE COLITIS AND CROHN'S DISEASE - The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype. | 01-16-2014 |
20130317093 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH APO A-1 MILANO - This invention relates to the treatment of Alzheimer's disease, the reduction of the progression of Alzheimer's disease, and the alleviation of symptoms of Alzheimer's disease by administering ApoA-1 Milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an rAAV vector encoding ApoA-1 Milano or an active fragment thereof, to a mammal having Alzheimer's disease or a symptom of Alzheimer's disease. | 11-28-2013 |
20130302362 | Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100 - Immunostimulatory agents, T cell, compositions, methods and systems for treating and/or preventing various conditions in a human individual. | 11-14-2013 |
20130295062 | METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to methods and compositions for use in the treatment of neurological disorders, such as Alzheimer's disease and dementia. In one embodiment, the present invention provides a method of treatment of Alzheimer's disease in an individual by administering a composition overexpressing ACE to the individual. In another embodiment, the method of treatment comprises administering a composition comprising a therapeutically effective dosage of ACE. | 11-07-2013 |
20130236418 | Immunomodulatory Methods and Systems for Treatment and/or Prevention of Aneurysms - Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing an aneurysm and/or a condition associated thereto in an individual. | 09-12-2013 |
20130230487 | Immunomodulatory Methods and Systems for Treatment and/or Prevention of Hypertension - Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing hypertension and/or a condition associated thereto in an individual. | 09-05-2013 |
20130225430 | METHODS AND COMPOSITIONS FOR TREATMENT OF TOX-3 AND TFF-1 MEDIATED CANCER PATHOGENESIS - The present invention relates to biomarkers useful for the diagnosis, prognosis and treatment of cancer. In different embodiments, the invention relates to TOX3 and related biomarkers, such as TFF1, TFF3, AGR2, SCUBE2, CEACAM6, TSPAN1 or CXCR4. TOX3 and these related biomarkers are also useful for the characterization of different breast cancer disease subtypes. Also described herein are inventive compositions and methods drawn to the use of anti-TOX3 antibodies, inducible TOX3 transgenic animal models, TOX3 nucleic acids, peptides, and small molecules for detection and modulation of TOX3 function and/or expression. | 08-29-2013 |
20130183378 | CD133 Epitopes - An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders. | 07-18-2013 |
20130183328 | CANCER VACCINES AND VACCINATION METHODS - Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein. | 07-18-2013 |
20130177647 | METHODS FOR MANIPULATING SATIETY - Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal. | 07-11-2013 |
20130173309 | PRIVACY AWARENESS TOOL - Systems and methods for applying sets of rules to data for providing useful information for review or action at an appropriate time. More specifically, embodiments of the present invention relate to applying rules to large data sets of audit information from clinical systems of one or more healthcare provider facilities to detect patterns of behaviors that may be of concern (e.g., potential privacy violations, objectivity concerns, fraudulent behavior, abnormal activity, etc.), and to address the behaviors through human or system review or action. The rules may be weighted, aggregated, and scored to facilitate the improved detection of patterns of certain behaviors occurring at one or more healthcare provider facilities. | 07-04-2013 |
20130171073 | TREATMENT OF PITUITARY CORTICOTROPH TUMORS USING R-ROSCOVITINE - The present invention describes methods of treating a pituitary tumor, methods of suppressing ACTH and/or corticosterone levels in an ACTH-secreting pituitary adenoma, methods of inhibiting the growth of an ACTH-secreting pituitary adenoma and methods of treating Cushing's disease. These methods can include providing a composition comprising R-roscovitin or a salt thereof and administering the composition to a mammalian subject in need thereof. | 07-04-2013 |
20130143948 | MST1 AS A PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET IN HUMAN CANCER - The present invention relates to MST1 and MST2 cancer biomarkers. The inventors demonstrate herein that MST1 and/or MST2 can be used as biomarkers for the detection and prognosis of prostate cancer. The invention further discloses that enforced expression of MST1 can be used to inhibit and/or suppress the progression of prostate cancer. | 06-06-2013 |
20130143231 | MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY - The present invention relates to prostate cancer (PCa). More specifically, the invention provides a MST1 phosphothreonine (pMST1-T120) antibody that can be used in various assays to study correlations between Mst1 function and T120 site phosphorylation. The present invention can also be used to determine disease development and/or progression of prostate cancer in a subject using the antibodies disclosed herein. | 06-06-2013 |
20130142760 | ATHEROSCLEROSIS INHIBITION VIA MODULATION OF MONOCYTE-MACROPHAGE PHENOTYPE USING APO A-I MILANO GENE TRANSFER - A method of changing the phenotype of monocytes and macrophages from a pro inflammatory MI phenotype to an anti-inflammatory M2 phenotype is disclosed. The method can comprises providing a composition comprising a recombinant adeno-associated virus (rAAV) vector comprising an exogenous gene encoding ApoA-1 Milano or a fragment thereof, and administering the composition to mammal in need thereof to change the phenotype of monocytes or macrophages from a pro inflammatory M1 phenotype to an anti inflammatory M2 phenotype. By changing the phenotype of monocytes or macrophages from a pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, atherosclerosis can be treated. A method of monitoring macrophage phenotypic switching and a method of assessing the efficacy of the treatment of atherosclerosis are also described. | 06-06-2013 |
20130136720 | METHODS OF USING FUT2 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus. | 05-30-2013 |
20130129679 | INTERFERON BETA AS ANTIBACTERIAL AGENTS - The present invention describes method of treating bacterial infections, including MRSA. In various embodiments, the methods can use interferon beta, which is found to have antimicrobial activity. In certain embodiments, the interferon beta can be human interferon beta. In other embodiments, the interferon beta can be mouse interferon beta. In further embodiments, the interferon beta can be human interferon beta containing amino acid substitutions to make the human interferon beta more cationic in neutral pH. | 05-23-2013 |
20130096169 | TREATMENT OF CANCER WITH BIO AND CHEMOTHERAPY - This invention relates to compositions and methods utilizing a chemotherapeutic drug and 6-bromoindirubin3′-oxime (BIO) for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that BIO works synergistically with chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells. | 04-18-2013 |
20130084261 | POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer. | 04-04-2013 |
20130066199 | TUMOR MARGIN DETECTION METHOD BASED ON NUCLEAR MORPHOMETRY AND TISSUE TOPOLOGY - Systems and methods for detecting tumor margins are disclosed. The detection can be performed intra-operatively. A device is provided for housing a tissue sample during optical analysis for detection of tumor margins. | 03-14-2013 |
20130058953 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 03-07-2013 |
20130058918 | ISOLATION AND USE OF A NEW TYPE OF GLIAL CELL WITH NEUROTOXIC POTENTIAL - The present invention provides for an isolated population of aberrant astrocytes, methods of isolating the aberrant astrocytes, methods of diagnosing neurodegenerative diseases, methods of drug screening using the aberrant astrocytes, and treatment methods targeting function, activity, and signaling associated with aberrant astrocytes. | 03-07-2013 |
20130034525 | BETA ISELETS-LIKE CELLS DERIVED FROM WHOLE BONE MARROW - The invention provides for methods of producing pancreatic precursor cells and insulin-producing cells from bone marrow. In various embodiments, bone marrow derived stem cells are differentiated into pancreatic precursor cells and insulin-producing cells. In various embodiments, bone marrow derived stem cells are artificially induced to express VEGF and/or PDX-1. These cells can be used to treat or ameliorate diabetes or symptoms of diabetes. | 02-07-2013 |
20130028898 | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS - The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier. | 01-31-2013 |
20130018600 | ESTIMATION OF ION CYCLOTRON RESONANCE PARAMETERS IN FOURIER TRANSFORM MASS SPECTROMETRY - The present invention comprises a method and system for accurate estimation of the ion cyclotron resonance (ICR) parameters in Fourier-transform mass spectrometry (FTMS/FT-ICR MS). The parameters are essential to estimating the mass to charge ratio of an ion from FT-ICR MS data, the intended purpose of the instrument. Achieving greater accuracy in the parameters assists in greater accuracy of the mass to charge ratio of an ion, and obtaining an accurate estimation of the mass to charge ratio of an ion further aides in detecting mass with sub-ppm accuracy. Estimating mass in this manner enhances identification and characterization of large molecules. The inventive method and system thereby enhances the data obtained by conventional FTMS by accurately estimating ICR parameters. Ultimately, accurate estimates of the masses of molecules and detection and characterization of molecules from FT-ICR MS data are obtained. | 01-17-2013 |
20130013274 | MASS SPECTROMETRY SYSTEMS - Described herein are methods that may be used related to mass spectrometry, such as mass spectrometry analysis, mass spectrometry calibration, identification of proteins/peptides by mass spectrometry and/or mass spectrometry data collection strategies. In one embodiment, the subject matter discloses a phase-modeling analysis method for identification of proteins or peptides by mass spectrometry. | 01-10-2013 |
20130013273 | MASS SPECTROMETRY SYSTEMS - Described herein are methods that may be used related to mass spectrometry, such as mass spectrometry analysis, mass spectrometry calibration, identification of proteins/peptides by mass spectrometry and/or mass spectrometry data collection strategies. In one embodiment, the subject matter discloses a phase-modeling analysis method for identification of proteins or peptides by mass spectrometry. | 01-10-2013 |
20130012604 | METHODS OF USING PRDM1 GENETIC VARIANTS TO PROGNOSE, DIAGNOSE AND TREAT INFLAMMATORY BOWEL DISEASE - Methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis are disclosed. | 01-10-2013 |
20130012602 | METHODS OF USING ZNF365 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the ZNF365 genetic locus | 01-10-2013 |
20130009052 | MASS SPECTROMETRY SYSTEMS - Described herein are methods that may be used related to mass spectrometry, such as mass spectrometry analysis, mass spectrometry calibration, identification of proteins/peptides by mass spectrometry and/or mass spectrometry data collection strategies. In one embodiment, the subject matter discloses a phase-modeling analysis method for identification of proteins or peptides by mass spectrometry. | 01-10-2013 |
20120328555 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER - The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. | 12-27-2012 |
20120310331 | METHODS AND APPARATUS FOR ATRIOVENTRICULAR VALVE REPAIR - Methods and devices are disclosed for minimally invasive procedures in the heart. In one application, a catheter is advanced from the left atrium through the mitral valve and along the left ventricular outflow tract to orient and stabilize the catheter and enable a procedure such as a “bow tie” repair of the mitral valve. Right heart procedures are also disclosed. | 12-06-2012 |
20120308567 | USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROLACTINOMA - The invention relates to methods and kits for the treatment of prevention of and lowering the chances of developing prolactinomas by the administration of a tyrosine kinase inhibitor, such as lapatinib. | 12-06-2012 |
20120304319 | TOX3 AS A BIOMARKER FOR BREAST CANCER - The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either over-express or inducibly express TOX3. | 11-29-2012 |
20120301470 | USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF CUSHING'S DISEASE AND HYPERCORTISOLISM - The invention relates to methods and kits for the treatment of, prevention of, and lowering the chances of developing Cushing's Disease and/or hypercortisolism by the administration of a tyrosine kinase inhibitor, such as gefitinib. | 11-29-2012 |
20120295849 | USE OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders. | 11-22-2012 |
20120294834 | REGENERATION OF, REESTABLISHING FUNCTION IN AND REPLACING MICROVASCULATURE IN ORGANS AND TISSUES - The invention provides compositions and methods involving the use of endothelial progenitor cells (EPC) to re-generate and/or reestablish a functioning microvasculature in damaged or ischemic organs and tissue. The invention also provides compositions and methods using EPC for replacing lost function in organ and tissue that is damaged, ischemic, or scarred. Such compositions and methods may find utility in, for instance, organs or tissues that have been damaged due to lack of vasculature. | 11-22-2012 |
20120263790 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 10-18-2012 |
20120258049 | POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING - Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided. | 10-11-2012 |
20120253102 | EXTERNAL MAGNETIC FORCE FOR TARGETED CELL DELIVERY WITH ENHANCED CELL RETENTION - Disclosed herein are compositions and methods for the improved delivery of cells to a target tissue. In some embodiments, the compositions comprise stem cells, in particular cardiac stem cells, and the target tissue is damaged or diseased cardiac tissue. In several embodiments, the methods, in combination with the compositions, yield enhanced delivery, retention, and/or engraftment of the cells into the target tissue, thereby inducing improved functional recovery. | 10-04-2012 |
20120245460 | METHOD OF DETERMINING ISCHEMIA USING PAIRED STRESS AND REST SCANS - A method of identifying perfusion abnormalities in a heart of a patient. The method is performed with a patient stress map including stress values, a patient rest map including rest values, and one or more normal maps. The normal maps may include a normal change limit map including change limits, and a normal stress limit map including stress limits. The stress and rest maps are co-registered with one another and the normal maps. The method includes creating a patient change map by subtracting the rest count values of the rest map from the stress count values of the co-registered stress map. Then, in some embodiments, the patient stress and change maps are jointly compared to the normal stress and change limit maps to detect one or more hypoperfused regions. In such embodiments, the one or more regions detected are identified as having perfusion abnormalities and optionally displayed. | 09-27-2012 |
20120243764 | METHOD AND SYSTEM FOR PLAQUE CHARACTERIZATION - A method of quantifying plaques imaged by cardiac computed tomography angiography (“CCTA”) scan data. Calcified and non-calcified component thresholds are determined based at least in part on attenuation values of a pool of blood in the CCTA scan data. An epicardial fat threshold is determined and used to classify epicardial fat in the CCTA scan data. A portion of CCTA scan data positioned between a detected outer boundary of the coronary artery and a portion classified as lumen is classified as arterial wall. NCP and CP seeds are identified in the arterial wall portion. Portions of the CCTA scan data continuous with a NCP seed and having attenuation values greater than an artery wall value and less than the NCP threshold are classified as NCP, and portions of the CCTA scan data continuous with the CP seed and having attenuation values greater than the CP threshold are classified as CP. | 09-27-2012 |
20120238562 | TREATMENT OF CANCER BY TARGETING MOLECULES THAT INFLUENCE MST1/STK4 SIGNALING - The invention relates to the treatment of prostate cancer. In various embodiments, the invention teaches a method of administering one or more compounds that inhibit a molecule that antagonizes the activity of tumor suppressor Mst1 and Mst2 pathway signaling. In certain embodiments, one or more of the compounds include an mTOR and PI3K inhibitor. | 09-20-2012 |
20120238532 | TREATMENT OF HUMAN OSTEOSARCOMA - The present invention describes the combination of cucurbitacin (CuB) with methotrexate (MTX) for the treatment of cancers, including osteosarcoma. It was discovered that CuB and MTX have synergistic activity against osteosarcoma, which reduces toxicities associated with both chemotherapeutic agents. The present invention also describes the use of CuB for the treatment of osteosarcoma. | 09-20-2012 |
20120238469 | DIAGNOSTIC BIOMARKER TO IDENTIFY WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers found in women that are at risk for preterm delivery. | 09-20-2012 |
20120223224 | METHOD FOR SIMULTANEOUS CALIBRATION OF MASS SPECTRA AND IDENTIFICATION OF PEPTIDES IN PROTEOMIC ANALYSIS - The invention relates to a mass spectrometry calibration system that may be performed in real-time using the information contained within a sample without the addition of specific calibrants. When applied to a sample, such as a proteomic sample, the calibration system may identify the exact masses of peptides in the sample. The system involves the use of mathematical algorithms that iteratively estimate the error in the measurement and update the calibration parameters accordingly; thereby resulting in peptide mass identification. | 09-06-2012 |
20120208900 | METHODS OF PREDICTING THE NEED FOR SURGERY IN CROHN'S DISEASE - The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment. | 08-16-2012 |
20120208212 | METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2, OMPC AND ASCA SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti- | 08-16-2012 |
20120197244 | TREATMENT FOR ANEURYSM - The invention relates to methods for treating, inhibiting, reducing the size of or preventing enlargement of, aneurysms in a subject by delivering thermal or cryo energy to the vasculature of the subject at or near the site of an existing or potential aneurysm. | 08-02-2012 |
20120195875 | DETECTION OF IMMUNE MODULATION RESULTING FROM REDUCED PROTEIN PHOSPHATASE 2A ACTIVITY - The inventors demonstrate herein that measuring the level of protein phosphatase 2A activity (PP2A) is useful for assessing immune modulation and susceptibility to infection in an individual. This invention is especially useful when applied to septic individuals, and individuals with chronic infections. The invention also teaches a method of prevention and treatment of secondary infections, as well as prevention and treatment of cancerous conditions. | 08-02-2012 |
20120192878 | METHODS OF DIAGNOSING AND MONITORING REJECTION MEDIATED BY ANTIBODIES - An intracellular cytokine flow cytometry (CFC) assay was developed to measure CD3− (non-T) cell response to allo-Ags expressed on peripheral blood mononuclear cells (allo-CFC-PBMC) and/or endothelial cells (allo-CFC-EC) by detecting intracellular gamma-interferon (IFN | 08-02-2012 |
20120190698 | METHODS OF PREDICTING THIOPURINE RESPONSE - The present invention relates to methods of predicting therapeutic efficacy of thiopurines in an individual by determining the presence of one or more risk variants. In one embodiment, the effective therapeutic efficacy of thiopurines is determined by the presence of risk variants at the genetic loci of HLA-DRB1, CREM, TAGAP, PLCL1, GPX4, SBNO2, MEF2A and/or LYSMD4. In another embodiment, the risk variants are located at the genetic loci of ARL4C, IL1R2, JAK2, 19q13, CARD9, SNAPC4, and/or 8q24. In another embodiment, the individual is has been diagnosed with inflammatory bowel disease. | 07-26-2012 |
20120190663 | USE OF FREE DNA AS AN EARLY PREDICTOR OF SEVERITY IN ACUTE PANCREATITIS - This invention provides methods of determining the risk of AP development in an individual, as well as the diagnosis, prognosis, and treatment of acute pancreatitis (AP) in an individual, by determining the presence or absence of significantly high levels of free serum DNA in the subject relative to levels in a healthy individual. In other embodiments, the invention further provides methods of determining the risk of severe AP development, prognosis, diagnosis, and treatment of a severe form of acute pancreatitis based upon the presence of significantly high levels of free serum DNA in the subject relative to an individual who has and maintains a mild form of acute pancreatitis. | 07-26-2012 |
20120189664 | CANCER STEM CELL ANTIGEN VACCINES AND METHODS - Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein. | 07-26-2012 |
20120172314 | Klotho Protein and Related Compounds for the Treatment and Diagnosis of Cancer - Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 07-05-2012 |
20120088730 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE - The present invention relates to the discovery that the two ACE domains can have very different effects on cytokine expression. In one embodiment, the present invention provides a method of regulating and/or treating a condition in a subject by administering a therapeutically effective dosage of site specific ACE inhibitor. In another embodiment, the condition is inflammation and/or immune response. | 04-12-2012 |
20120088245 | METHODS OF DIAGNOSING INSULIN RESISTANCE AND SENSITIVITY - Methods of diagnosing susceptibility to metabolic insulin resistance and other related conditions are disclosed. The method provides means of diagnosing susceptibility to insulin resistance in Hispanic Americans by determining the presence of a risk haplotype at the LPL locus, the LPIN1 locus, and/or elevated levels of gamma-glutamyl transferase. | 04-12-2012 |
20120079611 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY - This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBM such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis. | 03-29-2012 |
20120073585 | METHODS OF PREDICTING COMPLICATION AND SURGERY IN CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors. | 03-29-2012 |
20120070899 | EFFECTIVE VECTOR PLATFORM FOR GENE TRANSFER AND GENE THERAPY - The invention relates to the discovery that mutations of serine residues of an AAV capsid results in significantly greater transfection efficiency than the wild type AAV2 virus. In one embodiment, the present invention provides a method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein, where the inhibition of the phosphorylation of one or more serine residues results in a decrease of ubiquitination of the virus capsid protein in the cell. In another embodiment, one of the one or more serine residues is Serine 264. In another embodiment, the Serine 264 residue is mutated to Alanine (S 264 A). | 03-22-2012 |
20120041082 | METHODS OF USING SMAD3 AND JAK2 GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2 loci. | 02-16-2012 |
20120004181 | TARGETED DELIVERY SYSTEM - The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle. | 01-05-2012 |
20110305704 | ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI - Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described. | 12-15-2011 |
20110300112 | METHODS FOR ENHANCING YIELD OF STEM CELL CULTURES AND ENHANCING STEM CELL THERAPY - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies. | 12-08-2011 |
20110300111 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS - Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration peptide so that a reprogrammed mammalian cell that exhibits at least one characteristic of pluripotency is generated. Also presented herein are methods for cardiac differentiation of a mammalian cell without the use of viral or plasmid vectors. In one aspect, such methods involve contacting a mammalian cell exhibiting at least one characteristic of pluripotency with a transducible polypeptide, so that cardiac differentiation of the cell occurs. | 12-08-2011 |
20110294726 | ANTIBIOTIC THERAPY TO REDUCE THE LIKELIHOOD OF DEVELOPING POST-INFECTIOUS IRRITABLE BOWEL SYNDROME - The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term irregular bowel pattern and reducing the likelihood of developing non-ulcer dyspepsia. The methods comprise providing an antibiotic and administering the antibiotic to a subject in need thereof. | 12-01-2011 |
20110286932 | OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE - The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively. | 11-24-2011 |
20110280834 | METHODS AND COMPOSITIONS FOR CARDIAC TISSUE REGENERATION - Methods for treating an injured cardiac tissue in a subject are provided herein. Methods for improving survival, engraftment and proliferation of stem cells in a cardiac tissue are provided. Also provided are methods for generating cardiac cells. Further provided are compositions for generating cardiac cells in a subject. | 11-17-2011 |
20110274708 | SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING - The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions. | 11-10-2011 |
20110269230 | METHODS AND COMPOSITIONS FOR MAINTAINING GENOMIC STABILITY IN CULTURED STEM CELLS - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies. | 11-03-2011 |
20110257458 | METHOD OF USING TUMOR CELL DEBRIS TO REDUCE BRAIN TUMOR RECURRENCE OR GROWTH - The present invention describes compositions comprising tumor cell debris, tumor lysate or tumor antigens and methods of using tumor cell debris, tumor lysate or tumor antigens for stimulating a specific immune response. The compositions may further comprise at least one TLR ligand. The stimulation of the specific immune response may be used to treat tumors, particularly, brain tumors. The treatment method may also reduce the recurrence of a tumor and/or inhibit or slow down the growth of a tumor. | 10-20-2011 |
20110256555 | USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1. | 10-20-2011 |
20110251162 | METHODS OF TREATMENT FOR MRSA INFECTIONS - The present subject matter relates to pathogenesis of MRSA. Specifically, the present disclosures identifies the pro-inflammatory properties of PVL as the cause of MRSA. Viewed from this new perspective, the present subject matter achieves novel methods and apparatus for treating MRSA infection in a subject involving the administration of an anti-inflammatory drug to the subject. Furthermore the present subject matter teaches methods and apparatus for treating a Panton-Valetine leukocidin associated infection in a subject involving the administration of an anti-inflammatory drug to the subject. | 10-13-2011 |
20110229471 | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD. | 09-22-2011 |
20110212048 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM - A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms. | 09-01-2011 |
20110189685 | METHODS OF USING JAK3 GENETIC VARIANTS TO DIAGNOSE AND PREDICT CROHN'S DISEASE - The present invention relates to methods of diagnosing and diagnosing susceptibility to Crohn's Disease by determining the presence or absence of risk variants at the JAK3 locus. In one embodiment, the present invention provides a method of diagnosing susceptibility to Crohn's Disease by determining the presence of a risk variant at the JAK3 locus, where the risk variant is associated with positive expression of ASCA and/or anti-I2. | 08-04-2011 |
20110177969 | THE ROLE OF IL17RD AND THE IL23-1L17 PATHWAY IN CROHN'S DISEASE - The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease. | 07-21-2011 |
20110177487 | METHODS AND APPARATUS FOR PERFUSION OF AN EXPLANTED DONOR HEART - Described herein are methods and apparatus that may be used in various applications, such as to extend the viability of a donor heart, promote the efficacy for transportation of a donor heart, and/or reduce costs associated with donor heart transport and preservation. In one embodiment, the subject matter discloses an effective method and apparatus for comprehensive cold perfusion of an explanted donor heart for improved preservation. | 07-21-2011 |
20110171232 | METHODS OF TREATING AUTOIMMUNE DISEASES CAUSED BY SMALL INTESTINAL BACTERIAL OVERGROWTH - Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases. | 07-14-2011 |
20110166223 | METHODS OF INHIBITING FGFR3 SIGNALING - Novel inhibitors of FGFR3 signaling having a structure shown as Formula 1 and a method of inhibiting FGFR3 signaling by administering a quantity of the inhibitor, or pharmaceutical equivalent, analog and/or salt thereof, to a mammal are disclosed. Additionally, the inhibitor may be used for treating one or more conditions associated with FGFR3 mediated signaling | 07-07-2011 |
20110160765 | METHODS AND DEVICES FOR TREATMENT OF FISTULAS - This invention relates to methods and devices utilizing minimally invasive techniques for digestive system fistula closure using occluder devices and various securing and sealing means. The present subject matter expands upon the breadth of current endoscopic techniques by implementing novel occluder devices and techniques intended specifically for treatment of digestive fistulas. | 06-30-2011 |
20110159523 | N-TERMINAL SPECIFIC CHEMICAL LABELING FOR PROTEOMICS APPLICATIONS - Described herein is a method that may be used in various applications, such as drug development, medical diognosis and gene/protein therapy. In one embodiment, the subject matter discloses an effective method for identification and quantification of large sets of proteins/peptides in vitro and cells in vivo. | 06-30-2011 |
20110124644 | METHODS OF DIAGNOSING AND CHARACTERIZING CANNABINOID SIGNALING IN CROHN'S DISEASE - Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, 12 and/or anti-Cbir1 antibodies are included | 05-26-2011 |
20110117552 | METHODS OF USING A NOD2/CARD15 HAPLOTYPE TO DIAGNOSE CROHN'S DISEASE - The present invention provides a method of diagnosing or predicting susceptibility to Crohn's disease in an individual by determining the presence or absence in the individual of a disease-predisposing haplotype containing a JW1 variant allele at the NOD2/CARD15 locus, where the presence of the disease-predisposing haplotype is diagnostic of or predictive of susceptibility to Crohn's disease. | 05-19-2011 |
20110111418 | USE OF IRON-RELATED PATHWAYS AND GENES FOR TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE - A collection of genetic variants having susceptability to, or protection from, Parkinson's Disease is provided. The variants are useful in method of diagnosing, prognosing, and treating Parkinson's Disease and related conditions | 05-12-2011 |
20110104210 | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS - Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate. | 05-05-2011 |
20110104175 | METHODS OF TREATMENT FOR PULMONARY FIBROSIS - The invention relates to compositions and methods for treating fibrosing lung diseases, reducing pulmonary cytokine production in animals, treating bleomycin induced lung disease and treating cancer. Specifically, the present subject matter incorporates inactivation of the N-terminal site of an angiotensin-converting enzyme and/or administration of AcSDKP. | 05-05-2011 |
20110098672 | BALLOON CATHETER AND METHODS FOR PERICARDIOCENTESIS AND PERCUTANEOUS PERICARDIOTOMY - The present subject matter describes a balloon catheter and methods of using the balloon catheter. The balloon catheter is particularly useful for pericardiocentesis and percutaneous pericardiotomy. | 04-28-2011 |
20110092435 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 04-21-2011 |
20110086804 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 04-14-2011 |
20110086073 | NANOMETER-SIZED PRODRUGS OF NSAIDs - The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions. | 04-14-2011 |
20110085974 | SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY - The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue. | 04-14-2011 |
20110020371 | POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer. | 01-27-2011 |
20110014200 | MONOCLONAL ANTIBODY THAT SUPPRESSES THYROTROPIN RECEPTOR CONSTITUTIVE ACTIVITY - This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancer | 01-20-2011 |
20110009473 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT - The present invention relates to the use of pituitary tumor transforming gene 1 (PTTG1) as a biomarker for diagnosing cancer as well as for determining cancer treatment responsiveness. In one embodiment, the present invention provides a method of treating cancer by inhibiting the expression of PTTG1, and administering a therapeutically effective amount of Aurora kinase inhibitor, HDAC inhibitor and/or ROS-generating agent. | 01-13-2011 |
20110008303 | METHODS FOR TREATMENT AND PREVENTION OF MRSA/MSSA - Described herein are methods for treating and preventing MRSA/MSSA. The present subject matter deviates from current treatment methods by introducing a controlled decolonization/recolonization method, which eradicates the host surface area of MRSA/MSSA, and colonizes the newly cleared surface area with a nonpathogenic or pathogenic bacteria capable of out-competing MRSA/MSSA. | 01-13-2011 |
20100331273 | SELF-ASSEMBLING COMPLEX FOR TARGETING CHEMICAL AGENTS TO CELLS - The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs. | 12-30-2010 |
20100297152 | METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER - Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer. | 11-25-2010 |
20100292174 | CASPASE INHIBITORS IN THE TREATMENT OF INFECTION-ASSOCIATED PRETERM DELIVERY - Apoptotic processes induced by infection of, or injury to, fetal and placental tissues have been implicated in preterm delivery. Thus, modulation of apoptotis constitutes a strategy for improving pregnancy outcome in women with intrauterine infections. Caspase inhibitors, including the pancaspase inhibitor Z-VAD-FMK, can be used to prevent apoptosis and, thus, prevent preterm delivery. Accordingly, compositions and methods comprising caspase inhibitors for prevention of preterm delivery are provided. | 11-18-2010 |
20100291222 | ANTIOXIDANT NANOSPHERE COMPRISING [1,2]-DITHIOLANE MOIETIES - The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are also described. Another aspect of this invention is the use of these antioxidant nanospheres for the preparation of antioxidant particulate delivery system of therapeutic agents. | 11-18-2010 |
20100284999 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 11-11-2010 |
20100280497 | TRANSCECAL ILEOSTOMY SET - Described herein is a transcecal ileostomy set including a balloon catheter equipped with a blocking balloon, which serves for obstruction of a small intestine, and a fixation balloon, which serves for fixation of the balloon catheter inside the large intestine when inflated. Furthermore, it includes a holder, adapted to be fixed to a patient's body from the outside, which serves for closing a large intestine wall by tightening a bioresorbable loop passing through the large intestine wall and abdominal wall. A rotary part of the plastic holder may be affixed with a protrusion serving as a block when turning to tighten the bioresorbable loop. | 11-04-2010 |
20100268289 | METHOD AND SYSTEM FOR THE PREDICTION OF CARDIAC ARRHYTHMIAS, MYOCARDIAL ISCHEMIA, AND OTHER DISEASED CONDITION OF THE HEART ASSOCIATED WITH ELEVATED SYMPATHETIC NEURAL DISCHARGES - Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges. | 10-21-2010 |
20100240077 | METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2 SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti- | 09-23-2010 |
20100240043 | METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus. | 09-23-2010 |
20100209507 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 08-19-2010 |
20100190162 | METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A. | 07-29-2010 |
20100184050 | DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE IN THE PUERTO RICAN POPULATION - This invention provides methods of diagnosis and treatment of inflammatory bowel disease. In one embodiment, the invention provides methods of diagnosing and/or predicting susceptibility for inflammatory bowel disease in the Puerto Rican population by determining the presence or absence of a risk variant at the HPS1 locus. In another embodiment, the invention further provides methods of diagnosing and/or predicting protection against inflammatory bowel disease by determining the presence or absence of a protective variant at the IRF1 locus. In another embodiment, the presence in an individual of a risk variant at the CARD8 locus is diagnostic of susceptibility to Crohn's Disease in a Puerto Rican individual. In another embodiment, the presence of a risk variant at the TLR-9 locus in an individual is diagnostic of susceptibility to Crohn's Disease. | 07-22-2010 |
20100183706 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 07-22-2010 |
20100173344 | METHODS FOR ISOLATING AND USING PITUITARY ADENOMA STEM CELLS AND PITUITARY ADENOMA CELLS - The present invention describes pituitary adenoma stem cells, pituitary carcinoma stem cells, a method of obtaining the stem cells, and a method of using the stem cells. Uses of the pituitary stem cells include but are not limited to producing pituitary hormones and identifying drugs to treat pituitary disease conditions or pituitary-related disease conditions. | 07-08-2010 |
20100170517 | CLOSED SUCTIONING AND RINSING METHODS AND TRACHEAL DEVICES - Described herein is a method and apparatus that may be used in various applications, such as medical treatment of humans and animals. In one embodiment, the subject matter discloses a method for evacuation of secretions in the tracheal tube of a patient during endotracheal intubation by incorporating the use of a novel closed suction tracheal device containing a dedicated primary liquid reservoir, and a volume liquid chamber for supplying the liquid for lavage. | 07-08-2010 |
20100144903 | METHODS OF DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus. | 06-10-2010 |
20100143304 | ADENOVIRAL VECTOR COMPRISING HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE AND A TRANSGENE FOR INCREASING THE EXPRESSION OF THE TRANSGENE - Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven β-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. β-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression. | 06-10-2010 |
20100137212 | USE OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders. | 06-03-2010 |
20100130871 | SPECTRAL IMAGING DEVICE FOR HIRSCHSPRUNG'S DISEASE - The subject matter disclosed herein relates to the field of spectral imaging in the diagnosis and treatment of Hirschsprung's disease. Devices and methods are provided that enhance and accurately diagnose Hirschsprung's disease intraoperatively using spectral imaging technology. | 05-27-2010 |
20100130600 | LIPOPROTEIN LIPASE AND ITS EFFECT ON STATIN TREATMENTS - The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus. | 05-27-2010 |
20100130423 | TREATMENT OF MYELOPROLIFERATIVE DISORDERS WITH ADAPTOR PROTEIN LNK - Janus kinase 2 (JAK2) associates with cytokine receptors and is essential for signal transduction in hematopoietic cells. The JAK2 mutation, JAK2 V617F, prevalent in myeloproliferative disorders, confers cytokine-independent proliferation and constitutive activation of downstream signaling pathways, when co-expressed with homodimeric type I cytokine receptors. The adaptor protein LnK is a negative regulator of hematopoietic cytokine receptors, including EPOR and MPL. LnK attenuates wild type JAK2 signaling in hematopoietic Ba/F3 cells expressing MPL. LnK also inhibits cytokine-independent growth and signaling conferred by JAK2 V617F in those cells. LnK, via its SH2 domain, PH domain, and other regions, associates with JAK2 and JAK2 V617F. Additional LnK domains are involved in LnK downregulation of JAK2 V617F constitutive activation. Elucidating the pathways that attenuate JAK2 and JAK2 V617F signaling provides insight into myeloproliferative disorders and helps to develop therapeutic approaches. Inhibition of Lnk enhances the expression of hematopoetic stem cells and hematopoetic progenitor cells. | 05-27-2010 |
20100105044 | ILEAL POUCH-ANAL ANASTOMOSIS (IPAA) FACTORS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - A common long term problem after Ileal Pouch-Anal Anastomosis (IPAA) is the inflammation of the pouch, called pouchitis. Additionally, about 5-10% of patients undergoing IPAA with a diagnosis of ulcerative colitis at the time of surgery are subsequently diagnosed with Crohn's disease. In one embodiment, the present invention provides methods of diagnosing and predicting susceptibility to pouchitis after IPAA by detecting the presence or absence of pANCA and/or Cbir1 Flagellin expression. | 04-29-2010 |
20100098653 | ANTIOXIDANT POLYMERS CONTAINING [1,2]-DITHIOLANE MOIETIES AND USES THEREOF - The present invention describes polymers containing 1,2-dithiolanes capable of acting as scavengers of free radicals, metals and reactive oxygen species. Also described are methods of synthesizing the antioxidant 1,2-dithiolane derivatives and polymerization thereof to produce biodegradable antioxidant polymers. The antioxidant polymers of the present invention may be used to treat diseases or conditions caused by oxidative stress and other free radical mediated conditions. The antioxidant polymers may also be used for the preparation of antioxidant particulate delivery devices of therapeutic agents. | 04-22-2010 |
20100087406 | INDUCTION OF INNATE IMMUNITY BY VITAMIN D3 AND ITS ANALOGS - Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D | 04-08-2010 |
20100068303 | TREATMENT OF CANCER WITH BIO AND CHEMOTHERAPY - This invention relates to compositions and methods utilizing a chemotherapeutic drug and 6-bromoindirubin3′-oxime (BIO) for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that BIO works synergistically with chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells. | 03-18-2010 |
20100063423 | ULTRASONIC BATH TO INCREASE TISSUE PERFUSION - The present invention describes a method of using an ultrasonic bath to enhance tissue perfusion, enhance the development of collateral blood vessels and/or enhance collateral circulation in an extremity in need thereof. Also described is an ultrasonic bath adapted to hold media and to permit the immersion of an extremity and comprising one or more ultrasonic transducers to generate and transmit ultrasonic energy to the extremity or the inventive method | 03-11-2010 |
20100062477 | METHODS OF ISOLATING AND PROPAGATING STEM CELLS FROM BENIGN TUMORS - The present invention describes benign tumor stem cells, a method of isolating the benign tumor stem cells, a method of generating the benign tumor stem cells and a method of using the benign tumor stem cells. Uses of the benign tumor stem cells, such as pituitary stem cells include but are not limited to producing pituitary hormones and identifying drugs to treat pituitary disease conditions or pituitary-related disease conditions. | 03-11-2010 |
20100061980 | ASSAYS TO PREDICT AND MONITOR ANTIBODY MEDIATED REJECTION OF TRANSPLANTED ALLOGRAFTS - The present invention is directed to assays that may be used to measure B cell reactivity to allo or donor antigens in patients, gauge the efficacy of desensitization treatment of these individuals, predict antibody mediated rejection, and monitor patients post transplant for antibody mediated rejection. | 03-11-2010 |
20100055700 | ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors. | 03-04-2010 |
20100055697 | POSITIVE SELECTION OF SERUM PROTEINS FOR PROTEOMIC ANALYSIS - This invention relates to methods and kits for positive selection of species of interest based on peptide/protein sequence from a biological sample. The species of interest may be proteins and/or peptides of interest which may be placed through a mass spectrometer to obtain a blood peptide/protein signature. The blood peptide/protein signature may be used in proteomic analysis. The techniques include but are not limited to the use of collectors comprising nucleic acid molecules to extract a composition that has a lower concentration of a high abundance species of interest from a sample. This limits the level of influence that any collectors species may have on the results of a mass spectra. | 03-04-2010 |
20100040585 | METHODS FOR ISOLATING AND USING HEMATOPOIETIC AND EMBRYONIC STEM CELLS OF THE PERITONEAL CAVITY - The invention relates to the isolation and use of hematopoietic and embryonic stem cells. Additionally, the inventors identified the peritoneal cavity as a new source of hematopoietic stem cells. In one embodiment, the invention provides methods of isolating progenitor and/or stem cells from the peritoneal cavity. In another embodiment, the invention provides methods of transporting progenitor and/or stem cells from the peritoneal cavity to another organ. In another embodiment, the present invention provides methods of regenerating bioengineered tissues and/or reconstituting an hematopoietic system. | 02-18-2010 |
20100021917 | METHODS OF USING GENES AND GENETIC VARIANTS TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility to inflammatory bowel disease by determining the presence or absence of genetic variants. In one embodiment, a the invention is practiced by determining the presence or absence of NOD2 variants in an individual where the presence of NOD2 variants are indicative of susceptibility to Crohn's Disease in the individual. In another embodiment, the invention further determines the presence or absence of TLR8 variants where the presence of TLR8 variants are inflammatory bowel disease in female individuals. In another embodiment, the invention further determines the presence or absence of TR2 variant P631H where the presence of TLR2 variant P631H is indicative of susceptibility to Crohn's Disease. | 01-28-2010 |
20100021455 | METHODS FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and/or small intestine. | 01-28-2010 |
20100016684 | ELECTRONIC DEVICE AND SYSTEM FOR DETECTING REJECTION IN TRANSPLANT RECIPIENTS - The current invention relates to an implantable device, system, method, and computer readable medium comprising computer executable components for detection of rejection of a cardiac allograft. Acute rejection and chronic rejection are the leading cause of death in heart transplant recipients post transplant. The current invention seeks to address this problem by providing methods, devices, systems and computer readable media comprising computer executable components to monitor the efficacy of immunosuppressant therapy and evaluate the degree of rejection in a cardiac allograft. To provide this functionality, an implantable device comprises sensors which measure physiologic parameters at specified intervals after the transplant procedure. These measured parameters are subsequently compared with baseline parameter data to detect rejection of the cardiac allograft. | 01-21-2010 |
20100015156 | DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN CHILDREN - This invention provides methods of diagnosing and predicting disease progression of Crohn's disease. In one embodiment, a method of the invention is practiced by determining the presence or absence of CARD15 variants R702W, G908R, and/or 1007insC in a pediatric individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, and/or pANCA in a pediatric individual | 01-21-2010 |
20100011997 | DOCKABLE COMPUTER STATION - The invention relates to a mobile cart adapted to engage with an item of stationary furniture and/or to other mobile carts. In one embodiment, the mobile cart contains one or more units configured to interact when the mobile cart and stationary item of furniture are secured to one another. In another embodiment, the mobile cart is a work station adapted to be moved among different locations. | 01-21-2010 |
20100004430 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 01-07-2010 |